G12/13-dependent signaling of G-protein-coupled receptors: Disease context and impact on drug discovery

Expert Opinion on Drug Discovery

Volumn 2, Issue 12, 2007, Pages 1591-1604

  Siehler, Sandra ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug discovery; G protein coupled receptor; G12 13; Rho GTPase nucleotide exchange factor; RhoA

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT 12; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT 13; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; RHO FACTOR; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; THROMBOXANE A2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ASTHMA; ATHEROSCLEROSIS; BINDING AFFINITY; BRAIN VASOSPASM; CELL ADHESION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 37349017567     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.12.1591     Document Type: Review

References (108)

1. JACOBY E, BOUHELAL R, GERSPACHER M, SEUWEN K: The 7 TM G-protein-coupled receptor target family. Chem. Med. Chem. (2006) 1(8):761-782.
2. FREDHOLM BB, HOKFELT T, MILLIGAN G: G-protein-coupled receptors: an update. Acta Physiol. (2007) 190(1):3-7.
3. HEPLER JR, GILMAN AG: G proteins. Trends Biochem. Sci. (1992) 17(10):383-387.
4. XIE GX, PALMER PP: How regulators of G protein signaling achieve selective regulation. J. Mol. Biol. (2007) 366(2):349-365.
5. ZHONG H, NEUBIG RR: Regulator of G protein signaling proteins: novel multifuncfional drug targets. J. Pharmacol. Exp. Ther. (2001) 297(3):837-845.
6. 12 family. Trends Pharmacol. Sci. (2005) 26(3): 146-154.
7. OFFERMANNS S: G-proteins as transducers in transmembrane signalling. Prog. Biophys. Mol. Biol. (2003) 83(2):101-130.
8. BIRNBAUMER L, BIRNBAUMER M: Signal transduction by G proteins: 1994 edition. J. Recept. Signal. Transduct. Res. (1995) 15(1-4):213-252.
9. SAH VP, SEASHOLTZ TM, SAGI SA, BROWN JH: The role of Rho in G protein-coupled receptor signal transduction. Ann. Rev. Pharmacol. Toxicol. (2000) 40:459-489.
10. WHEELER AP, RIDLEY AJ: Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. (2004) 301(1):43-49.
11. FUKUHARA S, CHIKUMI H, GUTKIND JS: RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho? Oncogene (2001) 20(13):1661-1668.
12. 12/13-induced signals to Rho GTPase. Cell Signal. (2004) 16(2):201-209.
13. NARUMIYA S, ISHIZAKI T, WATANABE N: Rho effectors and reorganization of actin cytoskeleton. FEBS Lett. (1997) 410(1):68-72.
14. RIENTO K, RIDLEY AJ: Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell. Biol. (2003) 4(6):446-456.
15. 13 subunits define a fourth class of G protein alpha subunits. Proc. Natl. Acad. Sci. USA (1991) 88(13):5582-5586.
16. 12 class of G proteins. Cell Signal. (1996) 8(4):235-245.
17. 12 subfamily of heterotrimeric G proteins: growth, migration, and metastasis. Biochemistry (2007) 46(23):6677-6687.
18. 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J. Biol. Chem. (1995) 270(42):24631-24634.
19. 12-induced RhoA activation. Biochem. Biophys. Res. Commun. (2005) 337(2):615-620.
20. q signaling pathways. Proc. Natl. Acad. Sci. USA (2002) 99(14):9352-9357.
21. 13 as key regulatory mediator in signal transduction. Life. Sci. (2003) 74(2-3):155-161.
22. 13 in agonist-induced vascular smooth muscle cell contraction. Circ. Res. (2000) 87(3):221-227.
23. SEASHOLTZ TM, MAJUMDAR M, BROWN JH: Rho as a mediator of G protein-coupled receptor signaling. Mol. Pharmacol. (1999) 55(6):949-956.
24. interact with Ser/Thr protein phosphatase type 5 and stimulate its phosphatase activity. Curr. Biol. (2002) 12(15):1353-1358.
25. 13 deficiency. Science (1997) 275(5299):533-536.
26. 13 in endothelial cells during embryonic development. Proc. Natl. Acad. Sci. USA (2005) 102(23):8281-8286.
27. OFFERMANNS S: New insights into the in vivo function of heterotrimeric G-proteins through gene deletion studies. Naunyn Schmiedebergs Arch. Pharmacol. (1999) 360(1):5-13.
28. 13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat. Med. (2003) 9(11): 1418-1422.
29. GREENBERG DL, MIZE GJ, TAKAYAMA TK: Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry (2003) 42(3):702-709.
30. 12/13- and rho-dependent activation of phospholipase C-ε by lysophosphatidic acid and thrombin receptors. Mol. Pharmacol. (2006) 69(6):2068-2075.
31. 12 family G proteins. Biochem. Biophys. Res. Commun. (2001) 289(5):1211-1217.
32. 3 subtype induces neurite retraction via small GTPase Rho. J. Biol. Chem. (1996) 271 (47):29780-29784.
33. 1 adenosine receptor activation inhibits neurite process formation by Rho kinase-mediated pathways. Neuroreport (2001) 12(14):3057-3063.
34. 6 receptors are coupled to Rho and Rho kinase activation in vascular myocytes. Am. J. Physiol. Heart Circ. Physiol. (2000) 278(6):H1661-HI751.
35. 13-protein subunit linkage of D5 dopamine receptors in the nephron. Hypertension (2003) 41 (3):604-660.
36. SGOURAKIS NG, BAGOS PG, HAMODRAKAS SJ: Prediction of the coupling specificity of GPCRs to four families of G-proteins using hidden Markov models and artificial neural networks. Bioinformatics (2005) 21(22):4101-4106.
37. 12 family determine selective coupling to receptors. J. Biol. Chem. (2003) 278(17):14936-14939.
38. DHANASEKARAN DN: Transducing the signals: a G protein takes a new identity. Sci. STKE (2006) 347:PE31.
39. 11. J. Biol. Chem. (2003) 278(31):28743-28749.
40. 2 receptor activity. Mol. Pharmacol. (2006) 69(4):1433-1440.
41. WETTSCHURECK N, OFFERMANNS S: Mammalian G proteins and their cell type specific functions. Physiol. Rev. (2005) 85(4):1159-1204.
42. BERRIDGE MJ: Inositol trisphosphate and calcium signalling. Nature (1993) 361(6410):315-325.
43. 12 and Ras family G-proteins. Biochem. J. (2004) 378(Part 1):129-139.
44. BUNNEY TD, KATAN M: Phospholipase Cε: linking second messengers and small GTPases. Trends Cell Biol. (2006) 16(12):640-648.
45. KELLEY GG, KAPROTH-JOSLIN KA, REKS SE, SMRCKA AV, WOJCIKIEWICZ RJ: G-protein-coupled receptor agonists activate endogenous phospholipase Cε and phospholipase Cβ3 in a temporally distinct manner. J. Biol. Chem. (2006) 281(5):2639-2648.
46. 13 proteins in the murine nervous system. Eur. J. Neurosci. (2002) 16(12):2333-2341.
47. ROSSMAN KL, DER CJ, SONDEK J: GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell. Biol. (2005) 6(2): 167-180.
48. GRABOCKA E, WEDEGAERTNER PB: Disruption of oligomerization induces nucleo-cytoplasmic shuttling of leukemia-associated RhoGEF. Mol. Pharmacol. (2007) 72:993-1002.
49. TAYA S, INAGAKI N, SENGIKU H et al.: Direct interaction of insulin-like growth factor-1 receptor with leukemia-associated Rho GEF. J. Cell Biol. (2001) 155(5):809-820.
50. CHIKUMI H, BARAC A, BEHBAHANI B et al.: Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene (2004) 23(1):233-240.
51. HART MJ, SHARMA S, ELMASRY N et al.: Identification of a novel guanine nucleotide exchange factor for the Rho GTPase. J. Biol. Chem. (1996) 271(41):25452-25458.
52. 13. Science (1998) 280(5372):2109-2111.
53. 13 and Rho exchange factors. J. Biol. Chem. (2002) 277(2):1174-1181.
54. 13. Science (1998) 280(5372):2112-2114.
55. 13 proteins. Methods Enzymol. (2004) 390:285-294.
56. 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF. Proc. Natl. Acad. Sci. USA (2003) 100(2):733-738.
57. MAO J, YUAN H, XIE W, SIMON MI, WU D: Specitic involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptors. J. Biol. Chem. (1998) 273(42):27118-27123.
58. FUKUHARA S, MURGA C, ZOHAR M, IGISHI T, GUTKIND JS: A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J. Biol. Chem. (1999) 274(9):5868-5879.
59. HOLINSTAT M, MEHTA D, KOZASA T, MINSHALL RD, MALIK AB: Protein kinase Cα-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement. J. Biol. Chem. (2003) 278(31):28793-28798.
60. BANERJEE J, WEDEGAERTNER PB: Identification of a novel sequence in PDZ-RhoGEF that mediates interaction with the actin cytoskeleton. Mol. Biol. Cell (2004) 15(4):1760-1775.
61. 13-dependent plasma membrane recruitment of p115RhoGEF. Biochem. J. (2003) 371(Part 3):709-720.
62. 13 mutations that disrupt interaction with p115RhoGEF. Oncogene (2005) 24(13):2155-2165.
63. 13-promoted plasma membrane recruitment. FEBS Lett. (2003) 540(1-3):211-216.
64. 13 signals via p115RhoGEF cascades regulating JNK1 and primitive endoderm formation. J. Biol. Chem. (2004) 279(52):54896-54904.
65. WANG Q, LIU M, KOZASA T, ROTHSTEIN JD, STERNWEIS PC, NEUBIG RR: Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J. Biol. Chem. (2004) 279(28):28831-28834.
66. YAMADA T, OHOKA Y, KOGO M, INAGAKI S: Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). J. Biol. Chem. (2005) 280(19):19358-19363.
67. 13. Mol. Pharmacol. (2006) 70(4):1461-1468.
68. 13-Rho axis. Nat. Cell Biol. (2003) 5(12):1095-1103.
69. 12-selective Rho-mediated stress fiber formation. J. Biol. Chem. (2001) 276(47):44247-44257.
70. DIVIANI D, ABUIN L, COTECCHIA S, PANSIER L: Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J. (2004) 23(14):2811-2820.
71. BAISAMY L, JURISCH N, DIVIANI D: Leucine zipper-mediated homo-oligomerization regulates the Rho-GEF activity of AKAP-Lbc. J. Biol. Chem. (2005) 280(15): 15405-15412.
72. FRANCIS SA, SHEN X, YOUNG JB, KAUL P, LERNER DJ: Rho GEF Lsc is required for normal polarization, migration, and adhesion of formyl-peptide-stimulated neutrophils. Blood (2006) 107(4):1627-1635.
73. KOURLAS PJ, STROUT MP, BECKNELL B et al.: Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor evidence for its fusion with MLL in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA (2000) 97(5):2145-2150.
74. 12 from Rho-mediated signaling. J. Biol. Chem. (2005) 280(18):18049-18055.
75. BHATTACHARYA M, BABWAH AV, FERGUSON SS: Small GTP-binding protein-coupled receptors. Biochem. Soc. Trans. (2004) 32(Part 6):1040-1044.
76. JAFFE AB, HALL A: Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. (2005) 21:247-269.
77. MICHAELSON D, SILLETTI J, MURPHY G, D'EUSTACHIO P, RUSH M, PHILIPS MR: Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J. Cell Biol. (2001) 152(1):111-126.
78. YONEMURA S, HIRAO-MINAKUCHI K, NISHIMURA Y: Rho localization in cells and tissues. Exp. Cell Res. (2004) 295(2):300-314.
79. WENNERBERG K, DER CJ: Rho-family GTPases: it's not only Rac and Rho (and I like it). J. Cell Sci. (2004) 117(Part 8):1301-1312.
80. MEHTA D, RAHMAN A, MALIK AB: Protein kinase C-α signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J. Biol. Chem. (2001) 276(25):22614-22620.
81. ROSENFELDT H, CASTELLONE MD, RANDAZZO PA, GUTKIND JS: Rac inhibits thrombin-induced Rho activation: evidence of a Pak-dependent GTPase crosstalk. J. Mol. Signal. (2006) 1(8):1-10.
82. MARINISSEN MJ, GUTKIND JS: Scaffold proteins dictate Rho GTPase-signaling specificity. Trends Sci. (2005) 30(8):423-426.
83. GROSSE R, COPELAND JW, NEWSOME TP, WAY M, TREISMAN R: A role for VASP in RhoA-diaphanous signalling to actin dynamics and SRF activity. EMBO J. (2003) 22(12):3050-3061.
84. TREISMAN R, ALBERTS AS, SAHAI E: Regulation of SRF activity by Rho family GTPases. Cold Spring Harb. Symp. Quant. Biol. (1998) 63:643-651.
85. BROWN JH, DEL RE DP, SUSSMAN MA: The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res. (2006) 98(6):730-742.
86. SAYAS CL, MORENO-FLORES MT, AVILA J, WANDOSELL F: The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. J. Biol. Chem. (1999) 274(52):37046-37052.
87. 12-RGS RhoGEF-RhoA signalling pathway regulates neurotransmitter release in C. elegans. EMBO J. (2006) 25(24):5884-5895.
88. DEL RE DP, MIYAMOTO S, BROWN JH: RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J. Biol. Chem. (2007) 282(11):8069-8078.
89. WATTERSON KR, RATZ PH, SPIEGEL S: The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal. (2005) 17(3):289-298.
90. 2. Cardiovasc. Res. (2003) 58(1):170-177.
91. CALO LA, PESSINA AC: RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J. Hypertens. (2007) 25(2):259-264.
92. KUME H, TAKEDA N, OGUMA T et al.: Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation. J. Pharmacol. Exp. Ther. (2007) 320(2):766-773.
93. SEASHOLTZ TM, BROWN JH: Rho signaling in vascular diseases. Mol. Interv. (2004) 4(6):348-357.
94. 13 family G proteins regulate marginal zone B cell maturation, migration, and polarization. J. Immunol. (2006) 177(5):2985-2993.
95. GOROVOY M, NEAMU R, NIU J et al.: RhoGDI-1 modulation of the activity of monomeric RhoGTPase RhoA regulates endothelial barrier function in mouse lungs. Circ. Res. (2007) 101(1):7-9.
96. 12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. USA (2006) 103(21):8173-8178.
97. TOUGE H, CHIKUMI H, IGISHI T et al.: Diverse activation states of RhoA in human lung cancer cells: contribution of G protein coupled receptors. Int. J. Oncol. (2007) 30(3):709-715.
98. BARR AJ, BRASS LF, MANNING DR: Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor-G protein coupling. J. Biol. Chem. (1997) 272(4):2223-2229.
99. 35S]GTPγS binding assays. Trends Pharmacol. Sci. (2003) 24(2):87-90.
100. 35S]GTPγS scintillation proximity assay: a powerful emerging technique for analysis of GPCR pharmacology. Trends Pharmacol. Sci. (2004) 25(8):400-401.
101. REN XD, SCHWARTZ MA: Determination of GTP loading on Rho. Methods Enzymol. (2000) 325:264-272.
102. PERTZ O, HODGSON L, KLEMKE RL, HAHN KM: Spatiotemporal dynamics of RhoA activity in migrating cells. Nature (2006) 440(7087):1069-1072.
103. YOSHIZAKI H, OHBA Y, KUROKAWA K et al.: Activity of Rho-family GTPases during cell division as visualized with FRET-based probes. J. Cell Biol. (2003) 162(2):223-232.
104. ZAYZAFOON M, MEYERS VE, MCDONALD JM: Microgravity: the immune response and bone. Immunol. Rev. (2005) 208:267-280.
105. HEIN P, FRANK M, HOFFMANN C, LOHSE MJ, BUNEMANN M: Dynamics of receptor/ G protein coupling in living cells. EMBO J. (2005) 24(23):4106-4114.
106. GALES C, REBOIS RV, HOGUE M et al.: Real-time monitoring of receptor and G-protein interactions in living cells. Nat. Methods (2005) 2(3): 177-184.
107. KENAKIN T: Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. (2002) 1(2):103-110.
108. URBAN JD, CLARKE WP, VON ZASTROW M et al.: Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. (2007) 320(1):1-13. Excellent recent review of functional